Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P. Kumthekar
Bevacizumab in the Treatment of Glioblastoma: Is There an Optimal Dose or Schedule?
Related publications
Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma
Medical Oncology
Medicine
Cancer Research
Oncology
Hematology
Prophylactic Nitrate Therapy in Angina Pectoris-Is There an Optimal Treatment Regimen?
British Journal of Clinical Pharmacology
Pharmacology
Is There Optimal Behavioral Treatment Intensity for Dysphagia?
International Journal of Clinical & Experimental Otolaryngology
Efficacy and Safety of Bevacizumab for the Treatment of Glioblastoma
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Is There an Optimal Industry Financial Structure?
Update and Developments in the Treatment of Glioblastoma Multiforme &Ndash; Focus on Bevacizumab
Pharmacogenomics and Personalized Medicine
Molecular Medicine
Pharmacology
IP Restoration vs. WDM Protection: Is There an Optimal Choice?
IEEE Network
Information Systems
Computer Networks
Hardware
Communications
Architecture
Software
Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Single Dose Bevacizumab as Treatment for Symptomatic, Corticosteroid-Refractory Pseudoprogression After Chemoradiation Therapy for Newly Diagnosed Glioblastoma: A Case Report
Integrative Cancer Science and Therapeutics
